Ugedo L[au] - Search Results

Year	Number of Results
1984	1
1985	1
1986	1
1987	2
1988	1
1989	2
1990	1
1993	3
1995	2
1996	1
1997	4
1998	2
1999	2
2000	1
2001	4
2002	1
2003	3
2004	2
2005	1
2006	3
2007	3
2008	2
2009	2
2010	5
2011	3
2012	4
2013	5
2014	6
2015	5
2016	9
2017	6
2018	7
2019	8
2020	3
2021	3
2022	2
2023	1

1

Impairment of Serotonergic Transmission by the Antiparkinsonian Drug L-DOPA: Mechanisms and Clinical Implications.

Miguelez C, Benazzouz A, Ugedo L, De Deurwaerdère P. Miguelez C, et al. Among authors: ugedo l. Front Cell Neurosci. 2017 Sep 12;11:274. doi: 10.3389/fncel.2017.00274. eCollection 2017. Front Cell Neurosci. 2017. PMID: 28955204 Free PMC article. Review.

2

Nanodelivery of therapeutic agents in Parkinson's disease.

Lafuente JV, Requejo C, Ugedo L. Lafuente JV, et al. Among authors: ugedo l. Prog Brain Res. 2019;245:263-279. doi: 10.1016/bs.pbr.2019.03.004. Epub 2019 Apr 2. Prog Brain Res. 2019. PMID: 30961870 Review.

3

Dysfunction of serotonergic neurons in Parkinson's disease and dyskinesia.

Vegas-Suarez S, Paredes-Rodriguez E, Aristieta A, Lafuente JV, Miguelez C, Ugedo L. Vegas-Suarez S, et al. Among authors: ugedo l. Int Rev Neurobiol. 2019;146:259-279. doi: 10.1016/bs.irn.2019.06.013. Epub 2019 Jul 18. Int Rev Neurobiol. 2019. PMID: 31349930 Review.

4

Pharmacological treatment of Parkinson's disease: life beyond dopamine D2/D3 receptors?

Linazasoro G, Van Blercom N, Ugedo L, Ruiz Ortega JA. Linazasoro G, et al. Among authors: ugedo l. J Neural Transm (Vienna). 2008;115(3):431-41. doi: 10.1007/s00702-007-0852-z. Epub 2008 Feb 4. J Neural Transm (Vienna). 2008. PMID: 18250954 Review.

5

L-DOPA elicits non-vesicular releases of serotonin and dopamine in hemiparkinsonian rats in vivo.

Miguelez C, Navailles S, Delaville C, Marquis L, Lagière M, Benazzouz A, Ugedo L, De Deurwaerdère P. Miguelez C, et al. Among authors: ugedo l. Eur Neuropsychopharmacol. 2016 Aug;26(8):1297-309. doi: 10.1016/j.euroneuro.2016.05.004. Epub 2016 May 24. Eur Neuropsychopharmacol. 2016. PMID: 27234917

6

Serotonergic control of the glutamatergic neurons of the subthalamic nucleus.

Ugedo L, De Deurwaerdère P. Ugedo L, et al. Prog Brain Res. 2021;261:423-462. doi: 10.1016/bs.pbr.2020.11.003. Epub 2021 Jan 15. Prog Brain Res. 2021. PMID: 33785138

7

Interaction between the 5-HT system and the basal ganglia: functional implication and therapeutic perspective in Parkinson's disease.

Miguelez C, Morera-Herreras T, Torrecilla M, Ruiz-Ortega JA, Ugedo L. Miguelez C, et al. Among authors: ugedo l. Front Neural Circuits. 2014 Mar 17;8:21. doi: 10.3389/fncir.2014.00021. eCollection 2014. Front Neural Circuits. 2014. PMID: 24672433 Free PMC article. Review.

8

Cystine/glutamate antiporter blockage induces myelin degeneration.

Soria FN, Zabala A, Pampliega O, Palomino A, Miguelez C, Ugedo L, Sato H, Matute C, Domercq M. Soria FN, et al. Among authors: ugedo l. Glia. 2016 Aug;64(8):1381-95. doi: 10.1002/glia.23011. Epub 2016 Jun 1. Glia. 2016. PMID: 27247047

9

L-DOPA modifies the antidepressant-like effects of reboxetine and fluoxetine in rats.

Miguelez C, Berrocoso E, Mico JA, Ugedo L. Miguelez C, et al. Among authors: ugedo l. Neuropharmacology. 2013 Apr;67:349-58. doi: 10.1016/j.neuropharm.2012.11.016. Epub 2012 Dec 2. Neuropharmacology. 2013. PMID: 23211937 Free article.

10

The effect of 5-HT_1A receptor agonists on the entopeduncular nucleus is modified in 6-hydroxydopamine-lesioned rats.

Vegas-Suárez S, Aristieta A, Requejo C, Bengoetxea H, Lafuente JV, Miguelez C, Ugedo L. Vegas-Suárez S, et al. Among authors: ugedo l. Br J Pharmacol. 2021 Jun;178(12):2516-2532. doi: 10.1111/bph.15437. Epub 2021 May 6. Br J Pharmacol. 2021. PMID: 33686657 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results